Opinion|Videos|October 30, 2025
Impact of Recent Approvals and Novel Mechanisms
Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.
Advertisement
Episodes in this series
Panelists discuss how recent regulatory approvals and innovative therapeutic mechanisms are expanding options for EGFR-positive non–small cell lung cancer (NSCLC). They explore the benefits of dual-targeting agents such as amivantamab, which simultaneously inhibits EGFR and MET, and next-generation tyrosine kinase inhibitors (TKIs) such as sunvozertinib that address resistance mutations. The discussion incorporates findings from recent studies, including FLAURA2, which demonstrated improved survival with osimertinib plus chemotherapy, balanced against higher toxicity. Panelists note how these new treatments and subcutaneous formulations are driving a shift toward more durable, mechanism-based, and patient-centered care strategies.
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5